Date:2021-04-30 [close]
Call for Papers
Special Issue:
Current developments in the manufacture of pluripotent stem cell-based medicines: Proceedings of PSConf 2021
Guest editor: Prof Glyn Stacey
Deadline for submission: 30 November 2021
Expected publication date: 31 December 2021
The highly successful Pluripotent Stem Cell Conference 2021 (PSConf 2021), 21-26 April 2021 brought together international leaders in the development of human stem cell-based medicines to understand the current state-of-the-art and consider the needs of ongoing research in this area. The event included an International Symposium and Workshops on different aspects of human pluripotent stem cell (hPSC)-based manufacturing. The goal of this special issue will provide researchers from around the globe an opportunity to identify the current gaps in knowledge and technology and priorities for future research. This special issue offers an important opportunity to bring together world-renowned scientists and regulatory experts to address the technical challenges and consider current international regulatory science in this cutting-edge area. The special issue will rapidly publish contributions together with a summary of the meeting report of PSConf 2021 including insightful comments and feedback from all panelists and delegates. We cordially invite all speakers to submit a review of their state-of-the-art research advances presented during PSConf 2021.
Please submit your manuscript at: https://mc.manuscriptcentral.com/cellprolif
If you have any questions or concerns, please feel free to contact us:
Glyn Stacey glyn.stacey@iscbi.org
Jingyi Cao caojingyi@ioz.ac.cn
Appendix: Description of article types
Original Articles must be no longer than 6,000 words (including references), abstract of 275 words, no more than 50 references, and a title with no more than 120 characters (excluding spaces). Please include all relevant sections of the Methods section in the main manuscript (see submission types below). Manuscripts should include no more than 8 figures and tables, with a maximum of 6 panels per figure. We encourage you to submit additional methodological details, nonessential figures or portions of your manuscript as supplementary material for online publication only.
Submission types:
Reviews of both basic and clinical topics should be no longer than 6,000 words (including references). The reference list need not be exhaustive. While most reviews are invited by the Editors, authors interested in contributing reviews are requested to first contact the Editor or one of the Associate Editors with an outline of the proposed article.
Letters to the Editor may be subjected to peer review and undergo editing for clarity and brevity, and should be no longer than 500 words (including references) and include no more than 5 references and one figure. The Letters to the Editor section is not intended for the publication of original data.
Standards Public statement of what a representative group of experts agree to evidence-based and state of the art knowledge on an aspect of practice/policy.
Meeting Report Summary of development presented at a meeting, relying largely on the works presented at the meeting, not being fully referenced accounts of a field.
Tel: +86-10-64805072
fax: +86-10-64807316
e-mail: iscn@ioz.ac.cn
addr. : A3 Datun Road, Chaoyang District, Beijing, P.R.China 100101